Latest News and Press Releases

PRINCETON, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the Company will be added to the Russell 3000® and...

PRINCETON, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will...

FDA Approved Twirla® Expected to Reach Wholesalers in the Fourth Quarter of 2020 $93.9 Million in Cash and Cash Equivalents as of March 31, 2020 Management to Host Conference Call at 4:30 PM ET ...

Live Conference Call and Webcast at 4:30 p.m. ET PRINCETON, N.J., April 23, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today...

PRINCETON, N.J., April 22, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that the company has nominated Sharon...

PRINCETON, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that the Company will visit the Nasdaq...

PRINCETON, N.J., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of 15...

PRINCETON, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it intends to offer and sell shares of its common stock...

Current Cash and Cash Equivalents Expected to Meet Projected Operating Requirements through End of 2020 Twirla®, Company’s Lead Product Candidate, Receives FDA Approval Company Plans to Commence...

Twirla® is a new non-daily, non-invasive contraceptive approved in the U.S. PRINCETON, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX) (Agile or the...